BFM
ZNTL icon

Boothbay Fund Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Boothbay Fund Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-19,900
Closed -$1.33M – 2281
2021
Q3 		$1.33M Buy
+19,900
New +$1.15M 0.04% 626

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Boothbay Fund Management's ZNTL Position: Q2 2022 in Review

Boothbay Fund Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2022, closing a stake of 19,026 shares — an estimated $878K sold.

Boothbay Fund Management first reported a position in ZNTL in Q2 2021 and held it in 4 quarters. The position peaked at $1.6M in Q4 2021. 122 funds tracked by Wall St. Rank hold ZNTL as of Q2 2022.

  • Boothbay Fund Management reported no remaining Zentalis Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 19,026 Zentalis Pharmaceuticals shares in Q2 2022, an estimated $878K.
  • Boothbay Fund Management first reported a position in Zentalis Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • Boothbay Fund Management's Zentalis Pharmaceuticals position peaked at $1.6M in Q4 2021.
  • 122 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2022.

Based on Boothbay Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.